Article: PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab

Related products

• 

  1 year subscription print edition of the Belgian Journal of Hematology (BJH)

  €209.83 Add to cart
• 

  Article: Highlights in melanoma

  €3.03 Add to cart
• 

  Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma

  €3.03 Add to cart
• 

  Article: Highlights in respiratory oncology

  €3.03 Add to cart